Production (Stage)
ImmunityBio, Inc.
IBRX
$3.44
$0.299.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 41,172.50% | 5,084.17% | 7,160.98% | 2,314.63% | -88.89% |
| Total Other Revenue | -80.00% | 148.92% | 85.37% | 39.02% | -- |
| Total Revenue | 41,192.50% | 5,333.09% | 7,346.34% | 2,453.66% | -88.89% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 41,047.50% | 5,333.09% | 7,346.34% | 2,453.66% | -88.89% |
| SG&A Expenses | -21.53% | 25.13% | 11.47% | 49.63% | 25.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.00% | -9.08% | 7.66% | 17.84% | -14.92% |
| Operating Income | 32.32% | 17.87% | -0.15% | -16.66% | 14.68% |
| Income Before Tax | 3.15% | 74.65% | 10.34% | 2.63% | -15.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.33% | 74.65% | 10.34% | 2.63% | -15.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.76% | -22.73% | -61.67% | -94.01% | -91.25% |
| Net Income | 3.33% | 74.65% | 10.31% | 2.40% | -15.27% |
| EBIT | 32.32% | 17.87% | -0.15% | -16.66% | 14.68% |
| EBITDA | 33.14% | 18.36% | -0.33% | -17.98% | 15.21% |
| EPS Basic | 23.73% | 76.85% | 35.77% | 37.85% | 26.62% |
| Normalized Basic EPS | 23.68% | 76.86% | 35.73% | 37.74% | 26.49% |
| EPS Diluted | 24.00% | 73.37% | 25.13% | 37.50% | 26.36% |
| Normalized Diluted EPS | 23.68% | 76.90% | 35.89% | 37.74% | 26.49% |
| Average Basic Shares Outstanding | 26.80% | 9.51% | 39.63% | 57.03% | 57.06% |
| Average Diluted Shares Outstanding | 26.80% | 9.70% | 40.05% | 57.03% | 57.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |